CAR-T therapy in acute lymphoblastic leukemia (ALL): current clinical applications and beyond

Ella Peiwen Han

doi:10.54254/2753-8818/2024.LA18900

Article Information

Received: 27 September 2024

Published: 26 December 2024

DOI: https://doi.org/10.54254/2753-8818/2024.LA18900

Article Type: Research Article

Cite this article

Han,E.P. (2024). CAR-T therapy in acute lymphoblastic leukemia (ALL): current clinical applications and beyond. Theoretical and Natural Science,71,182-186.

Data availability

The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.

Disclaimer/Publisher's Note

The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

About this Volume

Volume Title: TNS Vol.71

Part of Series: Theoretical and Natural Science

ISSN: 2753-8818 (Print) / 2753-8826 (Online)

Copyright & License

[1]Jabbour, E., O'Brien, S., Konopleva, M., & Kantarjian, H. (2015). New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia. Cancer, 121(15), 2517–2528. https://doi.org/10.1002/cncr.29383

[2]Childhood Leukemia - Cancer Stat Facts. (2024). SEER. https://seer.cancer.gov/statfacts/html/childleuk.html

[3]Terwilliger, T., & Abdul-Hay, M. (2017). Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood cancer journal, 7(6), e577. https://doi.org/10.1038/bcj.2017.53

[4]Chen, Y. J., Abila, B., & Mostafa Kamel, Y. (2023). CAR-T: What Is Next?. Cancers, 15(3), 663. https://doi.org/10.3390/cancers15030663

[5]Cordoba, S., Onuoha, S., Thomas, S., Pignataro, D. S., Hough, R., Ghorashian, S., Vora, A., Bonney, D., Veys, P., Rao, K., Lucchini, G., Chiesa, R., Chu, J., Clark, L., Fung, M. M., Smith, K., Peticone, C., Al-Hajj, M., Baldan, V., Ferrari, M., … Amrolia, P. J. (2021). CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial. Nature medicine, 27(10), 1797–1805. https://doi.org/10.1038/s41591-021-01497-1

[6]Xu, X., Huang, S., Xiao, X., Sun, Q., Liang, X., Chen, S., Zhao, Z., Huo, Z., Tu, S., & Li, Y. (2021). Challenges and Clinical Strategies of CAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Overview and Developments. Frontiers in immunology, 11, 569117. https://doi.org/10.3389/fimmu.2020.569117

[7]Yang, J., He, J., Zhang, X., Li, J., Wang, Z., Zhang, Y., Qiu, L., Wu, Q., Sun, Z., Ye, X., Yin, W., Cao, W., Shen, L., Sersch, M., & Lu, P. (2022). Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: a first-in-human clinical study. Blood cancer journal, 12(7), 104. https://doi.org/10.1038/s41408-022-00694-6

[8]Pan, J., Niu, Q., Deng, B., Liu, S., Wu, T., Gao, Z., Liu, Z., Zhang, Y., Qu, X., Zhang, Y., Liu, S., Ling, Z., Lin, Y., Zhao, Y., Song, Y., Tan, X., Zhang, Y., Li, Z., Yin, Z., Chen, B., … Tong, C. (2019). CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia. Leukemia, 33(12), 2854–2866. https://doi.org/10.1038/s41375-019-0488-7

[9]Dai, H., Wu, Z., Jia, H., Tong, C., Guo, Y., Ti, D., Han, X., Liu, Y., Zhang, W., Wang, C., Zhang, Y., Chen, M., Yang, Q., Wang, Y., & Han, W. (2020). Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia. Journal of hematology & oncology, 13(1), 30. https://doi.org/10.1186/s13045-020-00856-8

[10]Liu, S., Deng, B., Yin, Z., Lin, Y., An, L., Liu, D., Pan, J., Yu, X., Chen, B., Wu, T., Chang, A. H., & Tong, C. (2021). Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation. American journal of hematology, 96(6), 671–679. https://doi.org/10.1002/ajh.26160

[11]Anderson, N. D., Birch, J., Accogli, T., Criado, I., Khabirova, E., Parks, C., Wood, Y., Young, M. D., Porter, T., Richardson, R., Albon, S. J., Popova, B., Lopes, A., Wynn, R., Hough, R., Gohil, S. H., Pule, M., Amrolia, P. J., Behjati, S., & Ghorashian, S. (2023). Transcriptional signatures associated with persisting CD19 CAR-T cells in children with leukemia. Nature medicine, 29(7), 1700–1709. https://doi.org/10.1038/s41591-023-02415-3

[12]Zhang, N., Shao, J., Li, H., Zhu, J., Xia, M., Chen, K., & Jiang, H. (2022). Humanized CD19-directed CAR-T Cell Therapy in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia With CNSL or Neurological Comorbidity. Journal of immunotherapy, 45(9), 396–406. https://doi.org/10.1097/CJI.0000000000000437

[13]Jacoby, E., Ghorashian, S., Vormoor, B., De Moerloose, B., Bodmer, N., Molostova, O., Yanir, A. D., Buechner, J., Elhasid, R., Bielorai, B., Rogosic, S., Dourthe, M. E., Maschan, M., Rossig, C., Toren, A., von Stackelberg, A., Locatelli, F., Bader, P., Zimmermann, M., Bourquin, J. P., … Baruchel, A. (2022). CD19 CAR T-cells for pediatric relapsed acute lymphoblastic leukemia with active CNS involvement: a retrospective international study. Leukemia, 36(6), 1525–1532. https://doi.org/10.1038/s41375-022-01546-9

[14]Zhang, X., Lu, X. A., Yang, J., Zhang, G., Li, J., Song, L., Su, Y., Shi, Y., Zhang, M., He, J., Song, D., Lv, F., Li, W., Wu, Y., Wang, H., Liu, H., Zhou, X., He, T., & Lu, P. (2020). Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features. Blood advances, 4(10), 2325–2338. https://doi.org/10.1182/bloodadvances.2020001466

[15]Sugita, M., Yamazaki, T., Alhomoud, M., Martinet, J., Latouche, J. B., Golden, E., Boyer, O., Van Besien, K., Formenti, S. C., Galluzzi, L., & Guzman, M. L. (2023). Radiation therapy improves CAR T cell activity in acute lymphoblastic leukemia. Cell death & disease, 14(5), 305. https://doi.org/10.1038/s41419-023-05829-6